在患有严重骨质疏松症的患者中,denosumab和romosozumab之间的新型顺序治疗方法
Shejil Kumar1,2,3, Matti L Gild2,3, Michelle M McDonald4,5
1Department of Diabetes & Endocrinology, Westmead Hospital, Sydney, Australia.
概括
在重症骨质疏松症患者中,一种新的重叠治疗策略使用denosumab和romosozumab,比标准方法更有效地改善了骨密度. 这种方法对高风险个体有希望,但需要进一步的研究.
科学领域:
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重骨质疏松症的管理需要有效的连续治疗策略.
- 德诺苏马布和罗莫苏马布之间的最佳测序尚未确定.
- 之前的研究表明,在从denosumab到romosozumab进行测序时,骨矿物质密度 (BMD) 增加有限,反弹抑制不足.
研究的目的:
- 评估在重症骨质疏松症患者中使用德诺苏马布和罗莫苏马布之间的新型重叠顺序治疗方法.
- 为了最大限度地提高骨矿物质密度 (BMD),使用romosozumab.
- 为了减轻在denosumab治疗后反弹骨周转率的风险.
主要方法:
- 在三名具有高骨折风险的严重骨质疏松症患者中,采用了一种新的重叠顺序治疗策略.
- 罗莫苏祖马布在最后一剂德诺苏祖马布剂量后三个月开始使用.
- 在开始罗莫苏祖马布治疗六个月后,由于骨周转率标志物上升,重新开始了德诺苏马布治疗.
主要成果:
- 经过12个月的罗莫苏祖马布治疗,患者在腰椎BMD (大约5-22%) 和部BMD (在一名患者中为8%) 显著增加.
- 罗莫苏马布 (Romosozumab) 显示出一种合成代谢效应,即使是在重叠的德诺苏马布治疗中.
- 重新启动的德诺苏马布成功抑制了骨再吸收标志物,并且没有发生新的脊椎骨折.
结论:
- 与标准方法相比,denosumab和romosozumab之间的新型重叠顺序治疗方法产生了优异的BMD改善.
- 这种策略可能对患有严重骨质疏松症和高骨折风险的患者有益.
- 需要进行更大规模的前性研究来验证这些发现并优化治疗方案.
相关概念视频
01:31Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
01:40Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
01:29Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
194
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
194